Treatment Strategies in Patients with MDS, MPN and AML

James K McCloskey, MD, Jamie L Koprivnikar, MD, and Christina Cho, MD discuss the diagnosis of myelodysplastic syndrome (MDS) and the importance of risk stratification in guiding treatment decisions.

An overview of the various treatment options available for patients with MDS, with an emphasis on the importance of tailoring treatment choices based on risk profiles.

Insights concerning unmet needs in MDS treatment, ongoing trials, and recent updates in the treatment landscape.

An overview of myeloproliferative neoplasms (MPNs) followed by an exploration of available treatment options and addressing differences in approach based on MPN subtypes such as essential thrombocytopenia, polycythemia vera, and myelofibrosis.

A closer look at the current unmet needs in MPN treatment, ongoing trials, and recent updates such as the MOMENTUM and FREEDOM trials.

Drs. Koprivnikar, McCloskey, and Cho delve into the diagnostic process in acute myeloid leukemia (AML), treatment approaches for AML, and factors influencing treatment selection.

Subject-matter experts highlight unmet needs in AML treatment, investigational therapies, and emerging targets showcased in recent studies.

Discussion centered around the role of allogeneic transplants in the treatment of MDS, MPN, and AML, focusing on the transplant process, eligibility criteria, patient selection, and post-transplant monitoring.